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Abstract (241 words) 
 
Objective: Childhood-onset type 1 diabetes is associated with neurocognitive deficits but 
there is limited evidence to date regarding associated neuroanatomical brain changes and 
their relationship to illness variables such as age at disease onset.  This report examines age-
related changes in volume and T2 relaxation time (a fundamental parameter of magnetic 
resonance imaging that reflects tissue health) across the whole brain.  
 
Research Design and Methods: Type 1 diabetes, N=79 (mean age 20.32 years, ± 4.24) and 
healthy control participants, N=50 (mean age 20.53 years, ± 3.60). There were no substantial 
group differences on SES, gender ratio or IQ.  
 
Results: Regression analyses revealed a negative correlation between age and brain changes, 
with decreasing gray matter volume and T2 relaxation time with age in multiple brain regions 
in the type 1 diabetes group. In comparison, the age-related decline in the control group was 
small. Examination of the interaction of group and age confirmed a group difference (type 1 
diabetes versus control) in the relationship between age and brain volume/T2 relaxation time.  
 
Conclusions: We demonstrated an interaction between age and group in predicting brain 
volumes and T2 relaxation time such that there was a decline in these outcomes in type 1 
diabetes participants that was much less evident in controls. Findings suggest the 
neurodevelopmental pathways of youth with type 1 diabetes have diverged from those of 
their healthy peers by late adolescence and early adulthood but the explanation for this 
phenomenon remains to be clarified. 
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Diabetes is a disorder of glucose metabolism in which blood glucose levels often fall 
outside the normal range, even when the disease is well controlled. The brain requires 
a constant supply of glucose to function normally and is one of the body systems 
potentially affected in type 1 diabetes. Severe hypoglycemia leads to uncontrolled 
release of excitatory amino acids, such as glutamate and aspartate, triggering a 
cascade of events that may result in neuronal damage (1), while chronically elevated 
glucose levels induce a form of glucose neurotoxicity (2). Variations in insulin and 
counter regulatory hormone levels may also be neurotoxic (3,4).   
 
There is a growing literature documenting central nervous system (CNS) changes in 
adults with type 1 diabetes including lower density of cortical gray matter (GM) and 
white matter (WM) lesions (4). Neuroimaging studies in children with type 1 diabetes 
have been limited to date and findings have implicated different brain regions and 
variable associations with illness-specific risk factors (5). These, albeit inconsistent 
findings, do suggest an adverse impact of type 1 diabetes on the developing brain, in 
line with evidence for neurocognitive deficits in childhood-onset type 1 diabetes (6). 
The exact nature, explanatory mechanisms and timing of CNS damage, however, 
remain to be clarified. 
 
Controlled studies that follow participants across childhood and into adulthood may 
be particularly informative in documenting the impact of type 1 diabetes on brain 
development. The Royal Children’s Hospital, Melbourne (RCH) Cohort Study 
recruited consecutive admissions with newly diagnosed type 1 diabetes between 1990 
and 1992, together with a healthy control group, into a longitudinal study.  Twelve 
years after diagnosis, a subset of the cohort underwent neuroimaging with magnetic 
 4
resonance imaging (MRI) to document structural changes in the CNS. Relative to 
controls, a number of brain regions in participants with type 1 diabetes showed 
decreased gray and white matter volumes and alterations in the T2 relaxation time, a 
fundamental MRI parameter that reflects the chemical environment of the brain and 
developmental changes such as myelination (7). In addition, we examined age-related 
volume loss and T2 relaxation time change in two brain regions, the thalamus and 
lentiform nuclei that were the areas of most widespread change in the analyses of 
group (type 1 diabetes versus control) differences. This report extends the initial 
analyses by examining the relationship between age with volume and T2 across the 
whole brain.  
  
 
Research Design and Methods 
Participants and procedure 
Consecutive admissions to RCH with newly diagnosed type 1 diabetes between 1990 
and 1992 (N=133), together with healthy controls (N=126), stratified for age and 
gender, formed the original cohort. A history of neurological disease or trauma was an 
exclusion criterion. Twelve years after diabetes onset, 106 participants with type 1 
diabetes and 75 controls were re-assessed (see (7) for a full description of sample 
characteristics). All participants had a neurocognitive assessment (7). The present 
report documents findings for the subset of participants (type 1 diabetes, N=79, 
controls, N=50), who were consecutively invited to undergo neuroimaging until 
available funding was exhausted. There were no differences between type 1 diabetes 
participants who underwent neuroimaging and those who did not on age at disease 
onset, history of hypoglycemia or metabolic control. Blood glucose levels of diabetes 
participants were determined by capillary sample prior to neuroimaging to ensure a 
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reading between 4 and 18 mmol/l. This study was approved by the Human Ethics 
Research Committee of the Victorian Government Department of Human Services.   
Imaging 
MRI was carried out on a 3 T scanner (GE Healthcare, Milwaukee, USA). Quantitative 
assessment of volume changes was carried out using voxel-based morphometry (VBM) (8). 
For VBM, a fast spoiled gradient recalled echo at steady state (FSPGR) sequence was used 
(TR/TE/TI 13.8/2.7/500 ms, voxel size: 0.48×0.48×2 mm). For voxel-based relaxometry 
(VBR) (i.e. quantitative assessment of the T2 relaxation time) (9), a modified, optimised 
Carr-Purcell-Meiboom-Gill (CPMG) multi-echo sequence was used (8 echoes, TE=28.9-231 
ms, TR=6.24 sec, 24 slices, 5 mm slice thickness, in-plane voxel size: 0.94×1.88 mm). The 
slice plane was perpendicular to the long axis of the hippocampus. T2 maps were generated 
by fitting to a mono-exponential model with the inclusion of a baseline that minimizes the 
contribution of long T2 components (mainly cerebrospinal fluid) to the fit.  
 
Images were warped to standard space in which they could be compared and 
smoothed.  Smoothing kernels of 6 mm and 10 mm were applied to volumetric and T2 
images respectively. A larger smoothing kernel is necessary for the T2 analysis to 
eliminate the observation of artefactual signal changes at the boundaries between 
tissue and CSF where abrupt changes of the relaxation time are expected (10). All 
analyses were performed using SPM8 (http://www.fil.ion.ucl.ac.uk/spm8). Gray 
matter (GM) volumetric analyses were performed using optimized VBM. Voxel-wise 
T2 relaxation time changes were assessed using the approach of VBR (9).  
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Analyses:  
1. SPM voxel-based age-regression (separate groups) 
Relationships between the volume and relaxometry data sets and age were examined    
using the regression model in SPM8.  Spatial maps showing voxels with statistically 
significant regression coefficients were obtained separately for type 1 diabetes and 
control participants (threshold, p < 5×10-6 uncorrected). 
 
2. Age-regression including interaction term 
The analysis described above can reveal potential differences in the magnitude of the 
regression coefficient between the participant groups (type 1 diabetes or control), but 
does not directly address the hypothesis that this difference is indeed group-
dependent. In order to assess this, a model with an interaction term (group × age) was 
fitted. Both regional and whole brain voxel-based analyses were performed and are 
described in turn. 
2.1 Region of interest (ROI)-based interaction analysis: A general linear 
model was used to investigate the group by age interaction in pre-chosen, discrete 
brain regions we previously identified (7) as differing between type 1 diabetes 
participants and controls.  
2.2 SPM voxel-based interaction analysis: To extend the previous study (7) 
and to depict the global picture of the interaction across the whole brain, voxel-based 
analysis was carried out in SPM8 using a linear model like that above with the 
addition of the interaction term. Spatial maps showing voxels with statistically 
significant interaction of group and age were obtained (threshold, p < 0.001 
uncorrected, F-test).   
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Results  
Sample characteristics  
Sample characteristics are presented in Table 1. Type 1 diabetes participants and controls did 
not differ substantially on age, gender ratio, socioeconomic status, or full-scale IQ.  
 
1. SPM voxel-based age-regression (separate groups) 
The statistical parametric maps of the age regression coefficients for type 1 diabetes 
and control participants are shown in Figure 1a and 1b for the GM volumetric and T2 
data, respectively. Areas of age correlation were minimal in the control subjects, 
whereas participants with type 1 diabetes showed stronger and statistically significant 
negative age correlations (volumetric reduction with increasing age) in the lentiform 
and thalamic nuclei, and insular and cingulate cortices. Similarly, areas showing 
decreasing T2 relaxation time with increasing age were more widespread in 
participants with type 1 diabetes than in controls, and incorporated both cortical and 
subcortical brain regions, including frontal and temporal cortices. 
 
2. Age-regression including interaction term 
2.1 ROI-based interaction analysis 
Table 2 presents tests of the group by age interaction from the general linear models 
fitted for each ROI. It also shows the estimated age regression slopes (with 95% 
confidence intervals) separately for participants with type 1 diabetes and controls. The 
results are ordered in terms of the size of the effect for the diabetic group (R2). 
Volumetric analysis of GM showed group by age interactions in the left parietal 
insula, right precentral region, right superior frontal gyrus and right thalamus. For T2, 
statistically significant group by age interactions were evident bilaterally in the 
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caudate and in the lentiform nucleus; the slightly weaker statistical scores for the 
thalamus were consistent with the volumetric analysis. The estimates for the GM 
volume regression slopes in the separate groups showed a pattern consistent with the 
voxel-based age regression analysis. Slopes for the control group were small and 
close to zero, and slopes for the diabetes group were larger in absolute magnitude and 
negative. The slope estimates for T2 were generally negative for both groups, but 
stronger for the diabetes group than for the controls. 
2.2 SPM voxel-based interaction analysis  
The voxel-based analysis of the group by age interaction term indicated a pattern of 
similar, regionally specific areas to the ROI analyses (see Figure 2a and b). The areas of 
statistically significant interaction in the T2 statistical parametric map were generally larger 
and more extensive than those for the GM volume. Regions where the regression interaction 
term reached the statistical threshold (F-test, p<0.001 uncorrected) are listed as follows: 
GM volume: Bilateral insula, bilateral lentiform nuclei, bilateral precentral gyrus, right 
parahippocampal gyrus, left postcentral gyrus, inferior and superior frontal gyrus, bilateral 
thalami, left putamen, bilateral middle temporal GM, left superior temporal GM.  
T2 relaxation time: Bilateral insula, bilateral lentiform nuclei, bilateral cingulate, bilateral 
inferior frontal gyrus, bilateral superior temporal gyrus, bilateral medial frontal gyrus, 
caudate nucleus, bilateral precentral gyrus, left putamen, bilateral parahippocampal gyrus, 
inferior temporal gyrus.  
 
Conclusions  
This study examined age-related changes in brain volume and T2 relaxation times 
across the whole brain using both volumetric and relaxometry MR data. We found a 
negative relationship between age and brain volume and T2 relaxation time loss 
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across large areas of the brain in participants with type 1 diabetes while only minimal 
changes were evident in the healthy controls. These findings were confirmed by 
regional and voxel-based analyses, which showed greater regional and global age-
related reductions in brain volumes and T2 relaxation time in type 1 diabetes 
participants, compared to controls. The brain regions most affected in type 1 diabetes 
participants include the thalamus, lentiform nuclei, insula and areas in the frontal and 
temporal lobes. The findings of greater volume and T2 relaxation time decrease with 
age (and later diabetes onset) are somewhat counter-intuitive given conventional 
wisdom about the greater vulnerability of the very immature CNS, and the consistent 
association between very early onset disease (i.e. younger than 5-6 years) and 
neurocognitive deficits (6). 
 
Volume loss and T2 reductions are characteristic of normal ageing, thus our findings 
could be interpreted as “accelerated brain ageing”. MRI studies of healthy individuals 
have shown that brain volume increases during childhood, reaching a maximum in 
adolescence, thereafter declining in a fairly linear fashion, with acceleration in the rate 
of decline around 55 years of age (11). T2 relaxation time also changes in an age–
related manner across the life span. During early development, T2 relaxation time 
shortens, mainly reflecting the progression of myelination in white matter. In addition, 
a decrease in T2 relaxation time in extrapyramidal structures such as the putamen and 
caudate nucleus, clearly evident from around 20 years of age, reflects age-dependent 
accumulation of iron (12). It is interesting to note that the accelerated T2 reduction 
observed in the type 1 diabetes participants in this study includes several of these 
extrapyramidal brain regions which therefore may indicate a modified rate of iron 
deposition in these subjects. Indeed, elevated levels of iron have been found in blood 
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plasma in both type 1 and type 2 diabetes (13), which may be due to modified 
turnover of erythrocytes (14). The phenomenon of accelerated brain ageing in 
diabetes has previously been described by Biessels and colleagues (15) but only in 
older adults, and particularly, but not exclusively, in reference to type 2 diabetes. To 
our knowledge, this is the first study to raise the possibility of such an effect in a 
population of youth with type 1 diabetes and a mean age of just 20 years.  
 
Alternatively to a process of premature senescence, our findings might indicate some 
disruption to the final stages of neurodevelopment, in a process qualitatively different 
from the neurodegenerative changes postulated by Biessels and colleagues (15). Type 
1 diabetes, or an aspect of the disease, may impact on neurodevelopment such that 
youth with the disease show less normative age-related increase in brain volume. This 
is consistent with the findings in a recent study where the expected rate of increase in 
total WM volume during early development was not observed in a group of younger 
(3-10 years old) children with type 1 diabetes (16). Diabetes-related effects on GM 
may occur later in neurodevelopment, i.e. during adolescence. Perantie et al. (5) 
imaged a sample (mean age of approximately12 years) and found no overall 
differences in GM volume between those with type 1 diabetes and healthy controls. In 
contrast, Musen et al. (17) conducted voxel-based analyses of a sample of young 
adults with a mean age approximately 32 years and reported volume loss in frontal 
and temporal regions and left thalamus, brain regions that overlap considerably with 
our own findings (7). Taken together, these findings suggest that late adolescence-
early adulthood may be a “critical period” where the GM volumes of youth with type 
1 diabetes diverge from those of their healthy peers. This interpretation is consistent 
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with Ryan’s “diathesis” hypothesis (18), which posits that early exposure to 
hyperglycemia increases the vulnerability of the brain to subsequent CNS disruption. 
  
The mechanisms underlying neural changes in our cohort with type 1 diabetes are 
unclear. Hyperglycemia is linked to excessive activation of the polyol pathway with 
resulting formation of advanced glycation end products (AGEs) and atrophy, as well 
as increased oxidative stress associated with cell death (4).  Alternatively, as a 
consequence of elevated blood glucose levels, the cells may become desensitized to 
glucose due to saturation of their metabolic activity, endoplasmic reticulum stress or 
mitochondrial dysfunction. Glucose has been shown to act as a mitogen in some 
contexts such as human beta cells (19).  In a different context, hyperglycemia was 
shown to lead to myocyte cell death (20) and to reduced cell differentiation in 
endothelial progenitor cells that is indicative of advanced cell senescence (21). The 
effects observed in this study may suggest the existence of a cell-survival failsafe 
mechanism following sustained hyperglycemia in which glucotoxicity and apoptosis 
are avoided by desensitization to raised glucose levels such that the propensity for cell 
division is reduced. In addition, the interaction of age with diabetes demonstrated in 
this study may reflect diabetes-induced modulation of synaptic plasticity.  In groups 
of young and aged rats exposed to streptozotocin-induced (STZ) diabetes, the 
impairment in plasticity was shown to be greater in the older group, implying an 
interaction between ageing and plasticity-related dysfunction in a model of type 1 
diabetes (22).    
 
It is important to note that the CNS changes that we demonstrated are subtle and of 
uncertain functional significance, although we have previously reported lower school 
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completion rates in our cohort (7). Scans were scrutinized by a neuroradiologist (AM) 
and three participants only had abnormalities that required clinical investigation, two 
of whom were controls. While meta-analyses of both children (6) and adults (23) with 
type 1 diabetes confirm subtle neurocognitive deficits, and there is increasing 
evidence of structural brain changes (see (24) for review), the literature is difficult to 
interpret because of inconsistency across individual reports. Different methodologies 
and samples heterogeneous for age, age of disease onset, illness duration and 
metabolic control history almost certainly contribute to inconsistent findings. We 
have previously reported that neurocognitive deficits were greater in those with early 
onset (< 5 years) diabetes (7,25), yet brain volume and T2 reduction was most evident 
in our older and later onset participants. It is difficult to explain the lack of 
correspondence between structural CNS changes and functional neurocognitive 
deficits but this disassociation has been reported before (3,11). Lenroot and Giedd 
(26) caution that relationships between brain structures and cognition are rarely 
straightforward even in healthy youth. In our cohort, constant exposure to abnormal 
glycemic variation may disrupt skill acquisition in the very young child even in the 
absence of structural CNS change, while subtle changes in brain structure may 
precede global cognitive difficulties in the participants who were older at disease 
onset.  
 
It is possible that some, or all, of the pathophysiological processes described above 
have contributed to our findings of age-related brain volume loss and T2 reduction in 
type 1 diabetes participants. The selectively greater impact on our older participants 
suggests an interaction between disease effects and neurodevelopmental stage but 
serial imaging of a diabetic cohort through childhood to CNS maturity in a controlled 
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design would be necessary to confirm this. Further exploration to clarify age-related 
changes and the mechanisms underlying brain changes in type 1 diabetes in general, 
are important though, as animal studies have indicated that adjunctive neuro-
protective strategies may be possible using either systemic IGF-1 (27) or 
glucocorticoid receptor antagonists such as mifepristone (28). These strategies, 
though promising, are either untried or nascent in the human context.  
 
In the last 15 to 20 years, standards of care have improved vastly for young people 
with type 1 diabetes to the point that we rarely see evidence of traditional diabetes 
complications in paediatric diabetes clinics. The new frontier in diabetes research and 
care is to facilitate the pre-eminent developmental task of childhood and adolescence 
– optimal brain development and function. 
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  Table 1. Sample characteristics  
 
 Type 1 Diabetes 
(n=79) 
Control  
(n=50) 
t-score 
or χ2 df p-value 
Female gender, N (%) 32 (40.51) 24 (48.00) 0.70 1 0.4
Age in years, M (SD)  20.32 (4.26) 20.54 (3.60) -0.30 127 0.8
SES, M (SD) 4.31 (1.10) 4.22 (1.07) 0.42 127 0.7
Full-scale IQ, M (SD)  101.89 (12.56) 105.14 (13.07) -1.41 127 0.2
Age of diabetes onset in years, M (SD)  7.08 (3.64)   
Illness duration, M (SD)       13.25  (1.05)   
Most recent HbA1c, M (SD)  9.06 (1.71)
% of time HbA1c > 9%*, M (SD)  41.44 (26.48)
Hypoglycemia†, N (%) 39 (49.37)
BGL at imaging in mmol/l, (M, SD)  12.61 (5.36)
Abbreviations: confidence interval (CI), socio-economic status (SES), blood glucose level at time of 
assessment (BGL), mmol/l glycosylated hemoglobin level (HbA1C) 
*  Percentage of total time from diagnosis that HbA1c  was ≥ 9%  
† ≥1 episode of hypoglycemia with associated seizure or coma  
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Table 2:  Group age regression slopes and the interaction term (Group × Age) in brain 
regions 
  F p-value R2 β 95% CI for 
β 
p-value 
T1 volume        
Left parietal insula Group*age 11.01 0.001     
Diabetes    0.323 -0.70 -0.94, -0.47 <0.001 
Controls   0.000 -0.02 -0.38, 0.34 >0.9 
Right SFG Group*age 3.24 0.07     
Diabetes    0.144 -0.37 -0.57, -0.16 0.001 
Controls   0.002 -0.05 -0.35, 0.25 0.7 
Left/Right thalamus Group*age 4.55 0.04     
Diabetes    0.091 -0.27 -0.47, -0.08 0.007 
Controls   0.009 0.10 -0.20, 0.40 0.5 
Left thalamus Group*age 3.61 0.06     
 Diabetes    0.070 -0.26 -0.47, -0.04 0.02 
 Controls   0.008 0.10 -0.22, 0.41 0.5 
Right thalamus Group*age 4.42 0.04     
 Diabetes    0.068 -0.25 -0.46, -0.04 0.02 
 Controls   0.016 0.14 -0.18, 0.47 0.4  
Right parahippocampal Group*age 0.29 0.6     
Diabetes    0.049 -0.25 -0.51, 0.00 0.05 
Controls   0.012 -0.14 -0.50, 0.23 0.5 
Right precental Group*age 4.37 0.04     
 Diabetes    0.048 -0.20 -0.40, 0.00 0.05 
 Controls   0.026 0.19 -0.15, 0.53 0.3 
Right parietal postcentral Group*age 0.55 0.5     
 Diabetes    0.047 -0.23 -0.46, 0.01 0.06 
 Controls   0.004 -0.08 -0.42, 0.26 0.6 
Left ITG WM Group*age 2.59 0.1     
 Diabetes    0.046 0.18 -0.01, 0.37 0.06 
 Controls   0.007 -0.07 -0.31, 0.17 0.6 
Left temporal 
parahippocampal region 
WM/GM 
Group*age 3.28 0.07     
Diabetes    0.032 0.11 -0.03, 0.25 0.1 
Controls   0.022 -0.15 -0.44, 0.14 0.3 
Left insula WM Group*age 0.76 0.4     
 Diabetes    0.010 0.07 -0.09, 0.22 0.4 
 Controls   0.004 -0.07 -0.36, 0.23 0.7 
Left middle frontal gyrus 
WM 
Group*age 0.43 0.5     
Diabetes    0.008 -0.06 -0.19, 0.08 0.4 
Controls   0.027 -0.14 -0.39, 0.11 0.3 
Right temporal 
parahippocampal region 
WM/GM 
Group*age 1.67 0.2     
Diabetes    0.001 0.03 -0.16, 0.21 0.8 
Controls   0.052 -0.17 -0.37, 0.04 0.1 
Left MTG WM Group*age 0.24 0.6     
 Diabetes    0.000 -0.01 -0.16, 0.14 0.9 
 Controls   0.004 0.06 -0.25, 0.37 0.7 
T2         
Right caudate/right 
lentiform 
Group*age 10.44 0.002     
Diabetes    0.536 -5.46 -6.62, -4.29 <0.001 
Controls   0.286 -2.57 -3.75, -1.39 <0.001 
Left lentiform Group*age 11.40 0.001     
 Diabetes    0.518 -5.73 -7.00, -4.46 <0.001 
 Controls   0.259 -2.49 -3.71, -1.27 <0.001 
Left caudate Group*age 12.62 0.001     
 Diabetes    0.505 -6.97 -8.56, -5.38 <0.001 
 Controls   0.208 -2.70 -4.24, -1.17 0.001 
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Right lentiform Group*age 4.79 0.03     
 Diabetes    0.473 -4.96 -6.16, -3.75 <0.001 
 Controls   0.276 -2.88 -4.23, -1.53 <0.001 
Right caudate Group*age 13.63 <0.001     
 Diabetes    0.461 -6.32 -7.90, -4.75 <0.001 
 Controls   0.157 -2.04 -3.40, -0.67 0.004 
Right thalamus Group*age 3.10 0.08     
 Diabetes    0.355 -4.57 -5.99, -3.15 <0.001 
 Controls   0.301 -2.74 -3.95, -1.53 <0.001 
Right insular Group*age 3.62 0.06     
 Diabetes    0.351 -6.10 -8.00, -4.19 <0.001 
 Controls   0.180 -3.28 -5.31, -1.25 0.002 
Red Nucleus Group*age 2.26 0.1     
 Diabetes    0.317 -4.62 -6.18, -3.06 <0.001 
 Controls   0.264 -2.88 -4.28, -1.49 <0.001 
Left thalamus Group*age 3.04 0.08     
 Diabetes    0.277 -3.57 -4.90, -2.24 <0.001 
 Controls   0.221 -1.90 -2.93, -0.86 0.001 
Right frontal WM Group*age 0.182 0.7     
 Diabetes    0.169 -3.32 -5.01, -1.63 <0.001 
 Controls   0.149 -2.76 -4.66, -0.84 0.006 
Corpus callosum Group*age 1.16 0.3     
 Diabetes    0.166 -3.66 -5.55, -1.77 <0.001 
 Controls   0.094 -2.10 -4.00, -0.21 0.03 
Right parietal GM Group*age 0.28 0.6     
Diabetes    0.024 -1.02 -2.50, 0.47 0.176 
Controls   0.071 -1.64 -3.36, 0.08 0.061 
Abbreviations: WM, white matter; GM, grey matter; ITG, inferior temporal gyrus; MTG, 
medial temporal gyrus; SFG, superior frontal gyrus.   
Note. Results are ordered in terms of decreasing R2 values for the Diabetes group. For T1, the 
df for the F-statistic 1, 125. For T2, the df for the F-statistic is 1, 123.  The results for T1 
have been rescaled (multiplied by 10). 
 
 23
Figure legends: 
Figure 1 Maps of significant age regression carried out separately in diabetes and control 
subject groups for (a) T1-GM volumetry data and (b) T2 relaxometry. The statistical 
parametric maps indicate voxels where the regression coefficient reaches significance 
(p<5×10-6 uncorrected). Coronal “glass brain images” on the left display the total of 
significant voxels superimposed throughout the volume. On the right is a representative 
coronal slice of the statistical parametric map overlaid on a canonical T1-weighted image. 
The T-statistic color-scale is also shown. Smoothing kernels were 6 mm and 10 mm for 
volumetric and relaxometry data respectively. 
 
Figure 2  Group × Age interaction term for (a) T1-GM volumetry data and (b) T2 
relaxometry data. The statistical parametric maps indicate voxels where the regression 
interaction term reaches significance (F-test. p<0.001 uncorrected). Coronal glass brain 
images are shown next to a representative coronal slice of the statistical parametric map 
overlaid on a canonical T1-weighted image. Smoothing kernels were 6 mm and 10 mm for 
volumetric and relaxometry data respectively. 
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